Viropharma halts maribavir Phase III trial in liver transplant patients
This article was originally published in Scrip
ViroPharma has discontinued a 348-patient Phase III trial of its antiviral maribavir as prophylaxis for cytomegalovirus (CMV) disease in liver transplant patients, and all patients receiving the study drug will be moved to the current standard of care. The decision was based on the recent failure of another Phase III trial of maribavir in stem cell transplant patients, and a recommendation from the trial's independent data monitoring committee (ScripOnline, February 12th, 2009). Maribavir is not in clinical trials for any other indications.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.